Patients are being told to check their packs (Image: Anastasiia Sienotova via Getty Images)
Users of a common high blood pressure medication are being urged to check their medication following a manufacturing error. The Medicines and Healthcare products Regulatory Agency has announced that a batch of Ramipril is being recalled due to the issue.
It said on Monday: “Crescent Pharma Limited is recalling one batch of Ramipril 10mg Capsules as a precautionary measure due to a potential error at the manufacturing site. Crescent Pharma Limited has received one complaint to date, where it has been identified that, inside a sealed carton of Ramipril 10 mg Capsules Batch No.: GR174091, one blister pack of Ramipril 5 mg Capsules Batch No.: GR164094 was found.
“Both product batches were manufactured at the same manufacturing site and the error appears to have occurred during secondary packaging of the cartons of Batch GR174091. Please note this is a Class 2 Patient, Pharmacy and Wholesaler level recall.”
The MHRA has instructed healthcare professionals to immediately cease supplying the affected batch. They have additionally been directed to quarantine all remaining stock and return it to their supplier.
It added: “If batch/product traceability information is available, pharmacy professionals and other healthcare professionals involved in dispensing medicinal products should identify and immediately contact all patients who have been dispensed the impacted product and ask them to confirm if they have remaining stock within their possession for return.
The incorrect capsules in 10mg packs (Image: MHRA)
Read more: Petrol station drive-offs surge 62% as fuel prices rocket
Read more: ‘My wife died aged 46 from rare disease after just one symptom’
“If batch/product traceability information is not available, pharmacists should identify all patients dispensed this product between 13 May 2025 and 16 April 2026. Where appropriate and feasible, contact all patients who have dispensed the impacted product with priority given to those who have been dispensed the product most recently and within the last 28 days. The majority of this was distributed in 2025 and therefore it is expected that many of these packs will have been dispensed to patients and consumed.”
The MHRA is alerting patients that certain cartons of Ramipril 10mg Capsules, produced by Crescent Pharma Limited, may contain blister strips of Ramipril 5mg Capsules, and that all packs from the affected batch of Ramipril 10mg Capsules (Batch Number GR174091) are being withdrawn as a precautionary measure.
Ramipril 10 mg Capsules – Batch GR174091 Outer carton and BN/Exp Date information (Image: MHRA)
It added: “If you were prescribed Ramipril 10 mg Capsules and have received the impacted product batch (Batch Number GR174091) please check that the carton contains the correct medication. The batch number and expiry date information can be found on outer carton.
“If the carton contains blister strips that are labelled and contain Ramipril 5 mg capsule, contact your dispensing pharmacy in the first instance. If the carton contains blister strips that are labelled and contain Ramipril 10 mg Capsules, you do not need to take further action.
“If you are unsure or have any questions, please seek advice from your pharmacy or other healthcare professionals responsible for your care. Please take the leaflet that came with your medicine and any remaining capsules with you to your pharmacy or GP practice.”
Ramipril 10 mg Capsules – Batch GR174091 Outer carton and BN/Exp Date information (Image: MHRA)
The MHRA clarified that both strengths of the capsule were prescribed to treat high blood pressure, heart failure and kidney disease, adding that any potential effect of a reduced dose of ramipril was likely to be gradual rather than sudden or life-threatening.
Ramipril 5mg Capsule – Batch GR164094 incorrect blister strip (Image: MHRA)
Patients experiencing adverse reactions or harbouring any concerns regarding their medication were urged to seek medical attention. Any suspected adverse reactions should also be reported through the MHRA Yellow Card scheme.
